Ortiz R M, Cilley R E, Bartlett R H
Pediatr Clin North Am. 1987 Feb;34(1):39-46. doi: 10.1016/s0031-3955(16)36179-x.
ECMO is capable of safely supporting respiration and circulation in newborns with severe respiratory failure and a moribund clinical presentation. The results thus far suggest that term infants with respiratory failure are the best candidates for ECMO, with a survival rate of 83 per cent. Infants under 35 weeks' gestation have a very high incidence of intracranial hemorrhage. Consequently, we do not currently accept them for ECMO treatment. The outcome of the survivors is largely determined by the clinical condition before ECMO and by major complications. Research must be directed toward cost effectiveness, timing and earlier use, alternative vascular access, cannula and circuit design, and expanded indications.
体外膜肺氧合(ECMO)能够安全地支持患有严重呼吸衰竭且临床表现濒死的新生儿的呼吸和循环。目前的结果表明,患有呼吸衰竭的足月儿是接受ECMO治疗的最佳人选,其存活率为83%。妊娠35周以下的婴儿颅内出血发生率非常高。因此,我们目前不接受他们进行ECMO治疗。幸存者的预后在很大程度上取决于ECMO治疗前的临床状况和主要并发症。研究必须朝着成本效益、时机和更早使用、替代血管通路、插管和回路设计以及扩大适应症的方向进行。